Decline in Net Assets and Equity Ratio
First written in FY2018. 8 of 27 entries say "Worsened", first in FY2019-Q1. Latest entry: FY2026.
Sun moved to the "Worse" side of this theme in 2023, the same year as the typical company in this theme.
The whole theme swung hardest in 2025: 6 of 14 companies on the "Worse" side.
3 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Equity ratio (%) 89.5 89.7」
Consolidated net assets amounted to ¥4,818.1 million, and the equity ratio rose from 89.5% to 89.7%. Although the acquisition of treasury shares reduced net assets, the increase in retained earnings was greater. - FY2026-H1WorsenedAnnual report
「Net assets decreased by ¥716 million from ¥47,608 million to ¥46,892 million, while the equity ratio declined from 89.5% to 88.5%.」
Net assets at the end of the interim period decreased by ¥716 million from the end of the previous consolidated fiscal year, and the equity ratio also declined from 89.5% to 88.5%. An increase in treasury shares and a decrease in the foreign currency translation adjustment were cited as the main factors behind the decline. - FY2025-H1WorsenedAnnual report
「Net assets amounted to ¥3,346.4 million, a decrease of ¥379.5 million from the end of the previous consolidated fiscal year. The main factors behind the decrease were declines of ¥336.9 million in valuation difference on available-for-sale securities and ¥48.7 million in retained earnings.」
Net assets decreased from ¥3,725.9 million to ¥3,346.4 million, and the equity ratio also declined from 79.3% to 77.4%. The decreases in valuation difference on available-for-sale securities and retained earnings were cited as the main factors. - FY2024-Q3Net assets recovered, but the equity ratio declinedAnnual report
「Net assets amounted to ¥3,351.9 million, a decrease of ¥149.4 million from the end of the previous consolidated fiscal year.」
Net assets decreased by ¥149.4 million from the end of the previous consolidated fiscal year, but recovered from the level at the end of the previous quarter. The equity ratio declined from 83.6% to 79.2%. - FY2024-Q2WorsenedAnnual report
「Net assets amounted to ¥3,230 million, a decrease of ¥271.3 million from the end of the previous consolidated fiscal year.」
Net assets decreased from ¥3,501.4 million at the end of the previous fiscal year to ¥3,230 million, mainly due to a ¥468.1 million decrease in retained earnings and other factors. The equity ratio also declined from 83.6% to 79.7%. - FY2024-Q1WorsenedAnnual report
「Net assets amounted to ¥3,252.3 million, a decrease of ¥249 million from the end of the previous consolidated fiscal year.」
Net assets decreased from ¥3,501.4 million at the end of the previous consolidated fiscal year to ¥3,252.3 million, and the equity ratio also declined from 83.6% to 80.1%. A decrease in retained earnings and other factors were cited as the main reasons for the decline. - FY2023Significant increase in the equity ratio following deconsolidationAnnual report
「Total assets amounted to ¥4,175.8 million, a decrease of ¥4,032.9 million from the end of the previous consolidated fiscal year. The main factor behind the decrease was the transfer of Cellebrite, formerly a consolidated subsidiary of the Company, and its 13 subsidiaries to equity-method affiliates.」
The deconsolidation of Cellebrite and its 13 subsidiaries significantly reduced total assets and liabilities, and the equity ratio rose from 29.7% to 83.6%. - FY2023-Q3Increase in the equity ratio following deconsolidationAnnual report
「Net assets amounted to ¥3,483.8 million, an increase of ¥779.8 million from the end of the previous consolidated fiscal year.」
Net assets amounted to ¥3,483.8 million and the equity ratio was 80.9%. The deconsolidation of Cellebrite and other entities resulted in significant changes in the equity ratio, along with the scale of total assets and liabilities. - FY2023-Q2Net assets and the equity ratio improvedAnnual report
「Net assets amounted to ¥3,872.4 million, an increase of ¥1,168.3 million from the end of the previous consolidated fiscal year. The main factors were increases of ¥525.8 million in capital surplus and ¥593.5 million in retained earnings.」
Net assets increased from ¥2,704 million at the end of the previous consolidated fiscal year to ¥3,872.4 million, and the equity ratio also rose from 29.7% to 42.7%. Increases in capital surplus and retained earnings were cited as the main factors. - FY2023-Q1Improvement in net assets and the equity ratioAnnual report
「Net assets amounted to ¥3,347.4 million, an increase of ¥643.4 million from the end of the previous consolidated fiscal year.」
Net assets increased from ¥2,704 million to ¥3,347.4 million, and the equity ratio also rose from 29.7% to 38.6%. - FY2022Improvement in both net assets and the equity ratioAnnual report
「Net assets amounted to ¥2,704 million, an increase of ¥621.9 million from the end of the previous consolidated fiscal year. / Equity ratio: 29.7%」
Net assets increased from ¥2,082 million to ¥2,704 million, and the equity ratio also rose from 28.9% to 29.7%. - FY2022-Q3Increase in net assets, decline in equity ratioAnnual report
「Net assets amounted to ¥2,150.6 million, an increase of ¥68.5 million from the end of the previous consolidated fiscal year. / Equity ratio: 23.9」
Net assets increased by ¥68.5 million from the end of the previous fiscal year, mainly due to an increase in capital surplus following the sale of Cellebrite shares and other factors, while the equity ratio declined from 28.9% to 23.9%. - FY2022-Q2Increase in net assets following the sale of Cellebrite sharesAnnual report
「Net assets amounted to ¥3,615 million, an increase of ¥1,534 million from the end of the previous consolidated fiscal year. The main factor was an increase of ¥1,549 million in capital surplus, primarily due to the sale of Cellebrite shares held by the Company.」
The sale of Cellebrite shares increased capital surplus by ¥1,549 million, and net assets increased from ¥2,082 million to ¥3,615 million. The equity ratio also rose from 28.9% to 43.1%. - FY2022-Q1Increase in net assets; slight improvement in equity ratioAnnual report
「Net assets amounted to ¥2,211 million, an increase of ¥129 million from the end of the previous consolidated fiscal year.」
Net assets increased from ¥2,082 million at the end of the previous consolidated fiscal year to ¥2,211 million, while the equity ratio edged up from 28.9% to 29.1%. - FY2021Net assets increased, while the equity ratio declinedAnnual report
「Net assets amounted to ¥2,082 million, an increase of ¥221 million from the end of the previous consolidated fiscal year. / Equity ratio: 28.9%」
Net assets increased from ¥1,860 million to ¥2,082 million due to the exercise of share options and other factors, while the equity ratio declined from 30.1% to 28.9%. - FY2021-Q3Net assets edged up, while the equity ratio declinedAnnual report
「Net assets totaled ¥18,621 million, an increase of ¥15 million from the end of the previous consolidated fiscal year. / Equity ratio 27.8」
Net assets increased by ¥15 million from the end of the previous consolidated fiscal year, while the equity ratio declined from 30.2% to 27.8%. Net assets and the equity ratio moved in opposite directions. - FY2021-Q2WorsenedAnnual report
「Net assets totaled ¥18,275 million, a decrease of ¥329 million from the end of the previous consolidated fiscal year. The main factor behind the decrease was a decline in retained earnings resulting from a quarterly net loss attributable to owners of the parent of ¥547 million.」
Net assets decreased from ¥18,605 million at the end of the previous consolidated fiscal year to ¥18,275 million, while the equity ratio declined from 29.3% to 28.3%. - FY2020Net assets increased through the capital increase, but the equity ratio declinedAnnual report
「Net assets totaled ¥18,605 million, an increase of ¥8,551 million from the end of the previous consolidated fiscal year.」
Net assets increased from ¥10,054 million to ¥18,605 million through Cellebrite’s private placement and other measures, while the equity ratio declined from 32.2% to 29.1%. - FY2020-Q3Increase in net assets maintained after the capital increaseAnnual report
「Net assets totaled ¥18,905 million, an increase of ¥8,851 million from the end of the previous consolidated fiscal year.」
Net assets increased from ¥10,054 million at the end of the previous consolidated fiscal year to ¥18,905 million, confirming the stronger financial base following the private placement. However, net assets decreased from the end of the previous quarter. - FY2020-Q2RestatedAnnual report
「Net assets totaled ¥19,312 million, an increase of ¥9,258 million from the end of the previous consolidated fiscal year.」
Through Cellebrite’s private placement and other measures, net assets increased from ¥10,054 million at the end of March 2019 to ¥19,312 million, while the equity ratio rose from 32.2% to 37.0%. - FY2020-Q1MitigatedAnnual report
「Net assets 11,701,374 21,283,318 10,054,397 Equity ratio 40.6 39.0 32.2」
Through a private placement and other measures, net assets increased from ¥10,054 million at the end of March 2019 to ¥21,283 million, while the equity ratio rose from 32.2% to 39.0%. - FY2019-Q3WorsenedAnnual report
「Net assets 11,372,892 Equity ratio 36.9」
Net assets decreased from ¥12,149 million at the end of March 2018 to ¥11,372 million, while the equity ratio declined from 42.3% to 36.9%. - FY2019-Q2WorsenedAnnual report
「Net assets 11,468,678 Equity ratio 39.9」
Net assets decreased from ¥12,149 million at the end of the previous consolidated fiscal year to ¥11,468 million, while the equity ratio declined from 42.3% to 39.9%. - FY2019-Q1WorsenedAnnual report
「Net assets 11,701,374 Equity ratio 40.6」
Net assets decreased from ¥12,149 million at the end of the previous consolidated fiscal year to ¥11,701 million, while the equity ratio declined from 42.3% to 40.6%. - FY2018First statedAnnual report
「Net assets decreased by ¥2,653 million from the end of the previous consolidated fiscal year to ¥12,149 million, down 17.9% year on year.」
Net assets fell 17.9% from the end of the previous fiscal year to ¥12,149 million, while the equity ratio declined 7.5 percentage points from 49.8% to 42.3%.